Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Ceftolozane/tazobactam

Development of resistance in Pseudomonas aeruginosa infection: case report

    • 6 Accesses

    This is a preview of subscription content, log in to check access.

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

    Reference

    1. Boulant T, et al. A 2.5-Year Within-Patient Evolution of Pseudomonas aeruginosa Isolates with in Vivo Acquisition of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistance upon Treatment. Antimicrobial Agents and Chemotherapy 63: e01637-19, No. 12, Dec 2019. Available from: URL: http://doi.org/10.1128/AAC.01637-19

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Ceftolozane/tazobactam. Reactions Weekly 1790, 71 (2020). https://doi.org/10.1007/s40278-020-74690-5

    Download citation